Perioperative Pembrolizumab and Lenvatinib in Resectable Hepatocellular Carcinoma (HCC)

NCT05185739 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

60

Enrollment

OTHER

Sponsor class

Conditions

Hepatocellular Carcinoma

Interventions

DRUG: Pembrolizumab
DRUG: Lenvatinib
DRUG: Pembrolizumab and Lenvatinib

Sponsor

University College, London

Collaborators

[object Object]